Tilsotolimod Demonstrates Encouraging Activity, Safety in Early-Stage Melanoma

Source: Onc Live, May 2022

The synthetic Toll-like receptor 9 agonist, tilsotolimod (IMO-2125), reduced the sentinel lymph node (SLN) biopsy positivity rate vs placebo in patients with localized, excised melanoma, according to interim data from the phase 1 INTRIM-1 trial (NCT04126876).

Results showed that patients who received an injection of tilsotolimod following the excision of a primary tumor achieved a 70% lower SLN positivity rate vs those who were injected with placebo. Notably, the SLN positivity rate for patients who received the placebo was between 40% and 50%.

“This is an exciting result from tilsotolimod, and we are pleased for the patients and their families to whom it offers hope for the future,” Vincent Milano, chief executive officer, Idera Pharmaceuticals, Inc., stated in a press release. “These results, together with data supporting tilsotolimod’s mechanism of action and encouraging safety profile from across the array of earlier preclinical and clinical work, reinforce the potential of tilsotolimod to offer benefit to patients with certain cancers. As a result, we plan to actively pursue a strategic partnership for tilsotolimod so that its full potential for patients may continue to be explored.”

READ THE ORIGINAL FULL ARTICLE